On August 24, 2026, the U.S. Food and Drug Administration approved Janssen Biotech’s IMAAVY (nipocalimab-aahu) injection for adult and pediatric patients aged 12 years and older currently or previously treated with corticosteroids (1,2). This landmark decision represents the first therapy proven safe and effective specifically for warm autoimmune hemolytic anaemia (wAIHA). As a first-in-class treatment, IMAAVY offers clinical management for an underserved community that has h

Pancreatic ductal adenocarcinoma (PDAC) remains one of the most difficult challenges in modern oncology. It is a condition characterised by aggressive tumour growth and a high mortality rate, with a five-year survival rate that persists below 13% (1). Because the disease is often asymptomatic in its early stages, the majority of patients are diagnosed only after the cancer has become metastatic and unresectable. While this mutation drives the disease, the RAS protein was long

ILAE - Epilepsy Congress 2026 Date of event: September 5-9, 2026 Location: Athens, Greece The conference brings together the global cardiology community to explore breakthrough research, gain practical clinical insights, and connect with leading experts from around the world. Through keynote sessions, interactive discussions, and hands-on learning experiences, participants will discover the latest scientific advancements designed to enhance clinical practice and improve pati

Halfway through the year 2023, BioMarin bagged the approval for an “adeno-associated virus serotype 5 (AAV5)” gene therapy by the United States Food and Drug Administration (FDA). The therapy is for adults with a life-threatening and rare genetic condition known as Haemophilia A. In this article we will discuss about the novel therapy and the studies leading to its approval. Haemophilia A, also referred to as an X-linked disorder affects 1 in 5,000 male births. The sex-linke

Atherosclerotic cardiovascular disease (ASCVD) is a leading cause of morbidity and mortality worldwide, affecting over 500 million individuals globally and resulting in approximately 19 million deaths annually. It is caused by the build-up of plaque that leads to hardening of the arteries. It can limit blood flow through the arteries which can result in severe conditions such as coronary heart disease, stroke, angina, or peripheral artery disease. The control of traditional c

In the 2nd week of December 2024, the medical fraternity received a piece of heart-warming news about inhaled insulin. Cipla received approval for the distribution and marketing of Afrezza® an inhaled insulin in India. The product created by Mannkind Corporation can be a blessing for millions of Indians who have compliance issues with injectable insulin (1). About Afrezza® Afrezza® (inhalable insulin) is a promising, ultra-rapid-acting noninjectable insulin delivery option de

Alzheimer’s disease is a progressive neurodegenerative disorder that affects the brain, gradually impairing memory, reasoning, and behaviour. The disease is marked by the accumulation of abnormal protein deposits in the brain, specifically amyloid plaques and tau tangles. These deposits disrupt neural function and ultimately lead to brain cell death. Over time, individuals lose the ability to carry out daily tasks and experience significant personality and behavioural changes

According to recent estimates, there are around 2.14 million HIV cases in India. Around 83% of these are in the age group 15-49 years (1). Antiretroviral therapy is the common treatment strategy followed which involves taking a combination of HIV medicines daily, monthly, or every other month. Although there is no cure for HIV, prompt treatment can help HIV patients live a healthy life and reduce the risk of transmission (2). On June 18th, 2025, the USFDA approved Gilead's Y